Form 4 for RNAC Cartesian Therapeutics, Inc.
Accepted 2025-01-06 00:00:00 ET · period of report 2025-01-02 · accession 0001453687-25-000027 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-01-06 | 2025-01-02 | RNAC | Jewell Christopher M | CSO | A - Grant | $0.00 | +16.1K | 56.0K | +40% | $0 |
| D | 2025-01-06 | 2025-01-02 | RNAC | Jewell Christopher M | CSO | A - Grant | $0.00 | +47.4K | 47.4K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-01-02 | A | A | 16,100 | $0.00 | 56,040 | D | — | — | (F1) Each Restricted Stock Unit represents a contingent right to receive one share of common stock, which will vest as to 25% on January 2, 2026. The remainder of the underlying shares will vest in three equal annual installments thereafter so that the underlying shares will be fully vested on January 2, 2029. |
| 2 | Derivative | Employee Stock Option (right to buy) | 2025-01-02 | A | A | 47,400 | $0.00 | 47,400 | D | $16.93 · — to 2035-01-01 | 47,400 Common Stock | (F2) This option vests as to 25% on January 2, 2026. The remainder of the underlying shares will vest in three equal annual installments thereafter so that the underlying shares will be fully vested on January 2, 2029. |